IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: : MDL-07-1871

AVANDIA MARKETING, SALES PRACTICES AND : Philadelphia, Pennsylvania PRODUCTS LIABILITY : March 26, 2014

LITIGATION

: 12:32 a.m.

TRANSCRIPT OF HEARING BEFORE THE HONORABLE CYNTHIA M. RUFE UNITED STATES DISTRICT JUDGE

APPEARANCES:

For the Petitioner: DIANNE M. NAST, ESQUIRE

NastLaw, LLC

1101 Market Street

Suite 2801

Philadelphia, PA 19107

JOSEPH ZONIES, ESQUIRE Reilly Pozner, LLP 1900 Sixteenth Street

Suite 1700

Denver, CO 80202

VANCE R. ANDRUS, ESQUIRE Andrus Wagstaff, PC 7171 West Alaska Drive Suite 200

Lakewood, CO 80226

Transcribers Limited 17 Rickland Drive Sewell, NJ 08080 856-589-6100 - 856-589-9005 APPEARANCES: (continued)

For the Petitioner: BRYAN F. AYLSTOCK, ESQUIRE

Aylstock, Witkin, Kreis &

Overholtz, PLLC 17 East Main Street

Suite 200

Pensacola, FL 32502

STEVEN J. CORR, ESQUIRE

Jones Day

555 South Flower Street

Fiftieth Floor

Los Angeles, CA 90071

For the Respondent: THOMAS V. GIRARDI, ESQUIRE (Appearing by Video) KEITH D. GRIFFIN, ESQUIRE

Girardi/Keese

1126 Wilshire Boulevard Los Angeles, CA 90017

For GlaxoSmithKline: NINA M. GUSSACK, ESQUIRE

Pepper Hamilton, LLP 3000 Two Logan Square 18th and Arch Streets

Philadelphia, PA 19103-2799

- - -

Audio Operator: Erica Pratt

Transcribed by: Donna Anders

- - -

Proceedings recorded by electronic sound recording, transcript produced by computer-aided transcription service.

- - -

(The following was heard in open court at 1 2 12:32 p.m.) 3 THE COURT: Good afternoon, everyone. ALL: Good afternoon, Your Honor. 4 Please be seated. 5 THE COURT: Can -- can our California litigants please be 6 7 Can you hear me? seated. 8 MR. GIRARDI: Thank you, Your Honor. THE COURT: All right. I guess you can hear 9 10 me. That's good. This is a motion -- well, there are two 11 12 matters before the Court today involving essentially the 13 same parties, and we issued an order to show cause requested by the Plaintiffs' Advisory Committee in the 14 Avandia MDL 1871, that is, 2007-1871, Document Number 15 3901, which was filed on the 13th of March. 16 17 And in that regard we have present those persons that have filed the motion for order to show 18 cause as well as the respondents, and I have received a 19 20 response, and we're going to be taking testimony on that today as to the allegations and the responsive 21 22 allegations. 23 But for the record, we have Dianne Nast

MS. NAST: Yes, Your Honor.

24

25

present.

1	THE COURT: Good morning.
2	MS. NAST: Good morning.
3	THE COURT: Vance Andrus.
4	MR. ANDRUS: Yes, Your Honor.
5	THE COURT: Good morning.
6	Bryan Aylstock, good morning.
7	MR. AYLSTOCK: Good morning, Your Honor.
8	THE COURT: Tom Cartmell is not here today.
9	MR. ZONIES: Mr. Cartmell is on trial, Your
10	Honor.
11	THE COURT: Thank you. And that leads me to
12	you, Joseph Zonies.
13	MR. ZONIES: Good morning, Your Honor
14	THE COURT: Good morning.
15	MR. ZONIES: or afternoon.
16	THE COURT: And we did not request that Paul
17	Kiesel as the adjunct member of the Committee be present
18	today. Did anyone hear from him?
19	MS. NAST: No, we we did not. He's not
20	I don't know if he's I don't think he's on the
21	Advisory Committee. He's on the Fee Committee. So we
22	did not ask him to come.
23	THE COURT: And also we have present Steve
24	Corr.
25	MR. CORR: Yes, Your Honor. Good morning.

THE COURT: And on behalf of respondent in this matter, who is present by video?

MR. GIRARDI: Your Honor, Thomas Girardi is present.

MR. GRIFFIN: Your Honor, Keith Griffin is also present.

THE COURT: Thank you. And that's the one matter. As to the second matter, we've been asked to enter a temporary restraining order in a -- I would call this a related matter which is why we scheduled it for today.

And that is that in that matter, the petitioner is GlaxoSmithKline, the defendant in the MDL that is known as Avandia, and its counsel, Pepper Hamilton counsel, have filed for injunctive relief in the nature of emergency relief, and that is a matter that is a little more, not complicated, but a little more concerning the actual terms of the settlement under a Master Settlement Agreement.

And the response has been received, and we're also going to entertain argument and limited testimony on that.

I need to be sure that this Court maintains proper jurisdiction to enter any relief in this, and the one overriding concern I have is the Master Settlement

Agreement. I do not have a copy of it. And to do that, I would -- to have that, it would help me and I'd also need to know what other Courts may be doing about this at the request of any of the parties. And so we will address that in turn.

But, for now, I would like to address the motion for order to show cause. Mr. Griffin and Mr. Girardi, are either of you or both of you represented by any other counsel, or are you representing yourself?

MR. GIRARDI: Your Honor, no, we -- we're here. We're not represented by anybody else.

THE COURT: All right. Now, let's begin by having the petitioners in that matter address why they felt the need to ask the Court to intervene and enter an order to show cause. Mr. Zonies, Ms. Nast, who is going to address this at first?

MS. NAST: Good morning again, Your Honor.

THE COURT: Good morning.

MS. NAST: We have, if the Court permits it, we have evidence that we would like to present on this matter. We're assuming subject to whatever the Court rules, that Mr. Girardi will lead off as it's -- he's been ordered to show cause, and then we would follow.

THE COURT: All right.

MS. NAST: Okay.

THE COURT: Would you like to present an opening statement then? 2

3

4

5

6

7

8 9

10

11

12

13

14 15

16

17

18

19

20 21

22

23

24

25

MS. NAST: We've asked Mr. Zonies to present the evidence. I don't think we intend to present an opening statement.

MR. ZONIES: I could summarize for the Court and for Mr. Girardi as well, if the Court would like, what we intend to show.

> THE COURT: I think that would be appropriate. MR. ZONIES: Good afternoon, Your Honor.

Zonies on behalf of the Avandia Plaintiffs' Advisory Committee.

Your Honor, we -- we were informed by the Master, Mr. Chirls, and also by GSK that during the resolution process of the Girardi Keese Avandia cases that Girardi Keese, the firm, had expressed some reservations about complying with PTO 70 in making an assessment on the cases that they resolved with GSK and Avandia.

It became clear that, in fact, that Girardi Keese was going to take the position that they did not owe that assessment, so that is why we brought before the Court the motion for an order to show cause to try to understand more clearly the position of Girardi Keese.

What we will intend to demonstrate for the Court is, is that in the initial order appointing PSC members in this case, one of the initial Plaintiffs' Steering Committee members was indeed Paul Sizemore who at the time was a partner or in some way, shape or form affiliated as an attorney with the Girardi Keese firm as is demonstrated on the order appointing Mr. Sizemore. It says Paul Sizemore, Esquire, Girardi Keese.

Simply due to the appointment of Mr. Sizemore as a PSC member under the Court's PTO 70 order, paragraph three, a PSC member -- all cases in which a PSC member has a financial interest are deemed covered claims or covered cases, and therefore, an assessment is due on those. Frankly, we think that's largely the end of the story right there.

However, at some point in time Mr. Sizemore did leave the Girardi Keese firm. This was after Girardi Keese paid the initial assessment as a PSC member through a firm check and made numerous submissions for cost, et cetera, from the PSC from the common fund. When Mr. Sizemore left the Girardi Keese firm, Mr. Griffin and -- both Mr. Griffin and Mr. Girardi attended numerous PSC meetings where presentation of common benefit work was put forth.

As evidence of that, we have numerous

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Petitioner's Opening Statement documents, but the most compelling of which is Mr. Griffin's signature on PTO 70 participation agreement. If the Court recalls under PTO 70, if a firm desires to use common benefit materials created by the PSC, that firm is required often to sign a participation That was attached to PTO 70, and under that agreement. participation agreement, the firm agrees that all of the cases in which it has a financial interest are subject to the assessment. We have that document as well.

We also will show for the Court that, as a regular course of business, Mr. Andrus would send to Ms. Gussack and GSK's counsel a list of attorneys who had -who the PSC believed had committed to paying the assessment at that time. Those letters were also cc'd to the attorneys on the list, and they were asked if they had any disagreements, that they should come forward at the time, so that we could assess whether or not their concerns were real, and we could address them appropriately and ensure that those attorneys did not then receive work product.

Mr. Girardi was sent at least two of those letters that we'll show to the Court, and we've never received at that time any response to those letters wherein they were objecting.

While in his affidavit, Mr. Girardi says that

number for that.

And then we also, if necessary, have additional emails demonstrating their use of the entire trial package put together by the PSC.

Numerous -- every deposition that the PSC took was listed as a potential exhibit in the California cases, and to my knowledge, Your Honor, I believe we'll be able to show that the Girardi Keese firm, absent the work of Mr. Sizemore when he was at the firm, did not take a single liability deposition of a GSK corporate witness other than in a case specific arena, that Mr. -- that Girardi Keese intended to and did designate experts that this Court knows well, because this Court did Daubert for Dr. Jewell, Dr. Brinton, Dr. Parisian, and those were the experts that, amongst others, that the MDL had worked up that Girardi Keese had listed and intended to use at their trials and in response to summary judgment motions in California.

So in addition to being a PSC member, executing the participation agreement, I believe we may

Petitioner's Opening Statement 11 be able to show they also executed PTO 10. There was a 1 vast use of PSC material, created material in the 2 3 California cases. Also with Mr. Robins, we have Justin Kaufman 4 from Heard Robins here who will testify about the Heard 5 Robins, while a PSC member in this Court, and as the 6 7 Court knows, Mr. Robins had California cases and very 8 actively worked with Mr. Girardi and all of the California counsel in using primarily PSC-generated and 9 10 MDL-generated materials. As far as I know, all the documents were 11 12 actually documents with AV-MDL numbers, Avandia-MDL numbers on them that Mr. -- that Girardi Keese intended 13 to use at their trial. 14 15 THE COURT: Thank you. 16 MR. ZONIES: Thank you. 17 THE COURT: Mr. Girardi, would you like to 18 make an opening statement? MR. GIRARDI: Yes, Your Honor, if I could. 19 20 THE COURT: Please proceed. MR. GIRARDI: First of all -- yes, Your Honor. 21 First, I would like to thank the Court for 22

letting us do it this way. We only had one day notice,

Your Honor. I take these things very seriously, but it

was very accommodating of you to let us attend the thing

23

24

25

Respondent's Opening Statement for the Justice and so forth.

Your Honor, here's the story. We filed our cases in 2008 in California. We did not know if they were going to be transferred to the MDL. We were successful to keep the cases here. Sizemore was with us about four months before he was terminated -- or he left. And then all of the litigation took place in California.

Judge Elihu Berle was appointed by the Presiding Justice to handle these cases, and he handled them from 2008 until today. The fact of the matter is we made 105 court appearances before Judge Berle. The other fact is that we totally prepared these cases outside of any influence of the MDL.

We did request documents and as the defendant in the case said, would you mind just -- we've already produced documents. Would you mind getting a copy of those instead? So that was the big document situation that we got. That was an accommodation to the defendant. They had already produced them, so they said just get a copy of them.

Now then, we then handled every ounce of this case ourselves. Every motion that was filed was us. Every defense of every motion was us. And for the past six or -- six years, this is what we've done.

settlement have nothing to do with the terms and

25

Respondent's Opening Statement 14 conditions of the MDL from the standpoint of what the people got, et cetera. I personally negotiated the settlement. I criss-crossed the country five times, had specific meetings with respect to the settlement.

And quite frankly, Your Honor, I believe the evidence is we got four times as much money for heart attacks as the MDL, because of the preparation and work that we did, along with investing \$14 million of the firm's own money for the proper cost of preparing the case.

THE COURT: Well, as I understand it --MR. GIRARDI: Now --

THE COURT: -- Mr. Girardi, as I understand the process over the last seven years in this MDL, the PSC did not direct any particular firm's settlement agreements, did not intervene or interfere even when requested in other firms' negotiations with GSK. So you're not in any different position than any other one of them who had their firms and their firms' cases settled with GSK.

Those are separate. So I just want to clarify here that that will never be a ground in this proceeding upon which you can prevail.

So why don't you go back to whether or not you used the material and the discovery that was amassed in

Respondent's Opening Statement the MDL for your cases?

MR. GIRARDI: Your Honor, thank you. Excuse me, Your Honor, for stepping on your line.

We did all of our own discovery. We have all of our own experts. Your Honor, I don't think any of the -- the members of this Committee before this Court put in \$14 million. I don't think any of them made 105 court appearances, and I don't think any of them achieved the result that we achieved for our people because of those things.

So now then, a couple of issues. There is an issue that before we knew that we were able to keep the cases in California, Sizemore worked for four months or so while he was still with our firm. He was granted \$200,000, and we told that we didn't -- we didn't agree to it, we don't want it, we weren't part of it, and they kept the \$200,000 that they assigned to Sizemore while he was with our firm.

After he left our firm, he did work, and he picked up a couple of million bucks out of the -- out of the fees. But while he was with us, it was very nominal, and, Your Honor, we did sign an agreement, there is no question about it, but the agreement only pertains to those cases that we actually had at that time. The actual number of those cases is 240 cases

Respondent's Opening Statement which were approved, that's all, out of the more than 2,500 cases that we handled.

So for -- for us now to be asked to turn over \$10 million to these folks that didn't do a darn thing for us -- and as I say, with respect to the documents, this was just a suggestion of the defendant, that says, listen, we've produced these. Just -- let's get a copy of those, and we said fine, that was fine with us, as opposed to having them then go again and produce yet another round of documents.

None of our experts interfaced with any of their experts. We prepared the cases ourselves, and as I said, at a massive expense. So if -- if the Court is going to say we have to turn over \$10 million, it seems to us that it would be reasonable that they would have to reimburse some of our \$14 million of expense.

Because the reason we achieved this phenomenal result for our clients, much different than the results there, was because of what we did not only with respect to the negotiations, what we did with respect to procuring the great experts across the world, and how we presented the case, Your Honor. That's the truth.

THE COURT: Well, I expect to hear you testify about that and whatever documentation you can present from your video conference process, we will try and

Respondent's Opening Statement 17 facilitate for you. But I do see Nina Gussack on behalf of GSK?

MS. GUSSACK: Your Honor, if I may just be heard briefly, I'd like to remind Mr. Girardi and perhaps the Court may want to caution Mr. Girardi, that the terms of his settlement are confidential.

The Court has placed the pertinent documents under seal, and to the extent that there are terms, financial variables, they are to be maintained as confidential. I don't think that impairs Mr. Girardi's ability to make his argument, but I'd appreciate it if there was greater concern about the confidentiality of the terms.

THE COURT: Did you hear that, Mr. Girardi?
Could you hear that clearly?

MR. GIRARDI: I did, Your Honor, and we were just -- we were just telling the Court, we don't intend to spread this to anybody. On the other hand, if you have to make a decision, I think it's important that you know what went on. But this is just to you, Judge.

This is -- Your Honor, this isn't -- I didn't mean to say Judge. I -- that is the --

THE COURT: Well, I did not -- I did not previously seal this proceeding, and we're making a record of it obviously, and that record would be open to

MR. GIRARDI: No.

THE COURT: What was his position at that

23

24

25

time?

Respondent's Opening Statement

MR. GIRARDI: He was a lawyer who worked for the firm.

THE COURT: Would you call him a shareholder or an associate or an intern? What do you call him? What was his position?

MR. GIRARDI: I suppose associate would be what -- what I would call him.

THE COURT: All right.

MR. GIRARDI: As I say, he was only there for, I believe, four months during the course of this.

And, Your Honor, the agreement that was signed only applied to cases that we had at that time, and that agreement is very clear, and, maybe, Your Honor, you would permit us to file with the Court something more detailed for you to look at before making your decision. I know you have a busy calendar and so forth, but we would like to put forth some of this to you before you make a decision to charge us \$10 million for people who didn't do any --

THE COURT: Well, you keep saying 10 million, and I don't have -- I will not decide this on numbers.

That's not what I'm being asked to do here. I'm being asked to rule on exactly what happened, not how much you pay. All right?

I don't arbitrate under any Master Settlement

Respondent's Opening Statement

Agreement, Mr. Girardi. That is not included in anyone's agreement or I would never have approved it. That's for a board of arbitration, so as to the amount, that's not what's going on here.

It is clearly laid out in the motion here that, one, you did use, utilize MDL materials, discovery, amass expertise. Your employees did the same. And whether or not you having later cases in the California system negates that is really the issue that you're trying to get me to address, and I will. I think so because initially your firm, as far as the docket is concerned, had filed lawsuits directly into the MDL, not removed from the California State Court, isn't that so?

MR. GIRARDI: Your Honor, I think maybe

Sizemore did. I -- Your Honor, I can't answer that. I

don't want to mislead the Court.

of some proof when the dockets are presented, but we shouldn't have to get to that. Because you can agree, can you not, without wasting more time, that Mr. Sizemore worked for you and he was appointed as a member of the PSC at the time he worked for you, and he conducted all of his PSC activities for the time that he was employed by you as a member of the MDL and your firm?

MR. GIRARDI: Your Honor, all of the activities is the only thing I would question. He was part of that Committee for four months, I think it was, and he -- the Committee awarded him \$200,000 during that time frame that we said we don't want it, and the Committee still has it. So --

THE COURT: And that is really not -- not related to the issue at all. That is a separate matter, and I think --

MR. GIRARDI: Well --

THE COURT: -- this is about use of MDLacquired expertise and information. MDL includes both
parties in the MDL, the plaintiff as well as the
defendant, and we are going to address it on that level.
I really don't care how much money he made or didn't
make. It's really not relevant. The point is, what is
relevant is that he did actively engage in the work of
the MDL as a member of the PSC, and I think we better
take it from there.

So what would you like to present in terms of documents and testimony, because when we get to testimony now, that was your opening statement, we'll have to place you under oath, Mr. Griffin as well, if you're going to testify, Mr. Griffin. Mr. Girardi?

MR. GIRARDI: Your Honor, we could look at the

agreement that was -- that we entered into which clearly states it only affects those cases that we had at that time which I indicated to the Court that there were some four hundred and some cases, I believe, Your Honor, of which 225 were actually -- actually made the cut. And the agreement only talks about those cases that we have at that particular time.

The language on -- on page two, the second paragraph, clearly says that the -- it applies to the cases that we -- that we have a financial interest at the time we're doing this agreement.

So if, in fact, there is a claim during the four months of Sizemore, and this agreement which indicates those cases, I think that the only valid and appropriate and fair way to do this in light of what we did in these cases, all of our efforts, would be to assess us for the cases that actually were handled at the time that this agreement was signed pursuant to the terms of the agreement.

THE COURT: What was the date of your agreement, please?

MR. GIRARDI: Bear with me, please, Your Honor. I'm sorry. Okay.

MR. GRIFFIN: Your Honor, this is Keith Griffin. It's dated May 12, 2009.

THE COURT: The Master Settlement Agreement? 1 Is that what you're reading --2 3 MR. GRIFFIN: No. No, Your Honor. No, Your 4 I'm reading from the -- the agreement that Mr. Zonies referenced in his opening statement of a 5 participation agreement that was signed by -- by me, 6 7 Keith Griffin. 8 THE COURT: No. We're getting too many things mixed up. Would both of you rise to be sworn in, 9 10 please. We can do that long distance. COURTROOM DEPUTY: Please raise your right 11 12 hand. 13 THE COURT: Did they hear you? THOMAS GIRARDI, Respondent, Sworn. 14 15 KEITH GRIFFIN, Respondent, Sworn. 16 COURTROOM DEPUTY: Thank you. 17 THE COURT: Thank you. 18 All right. We know which one is which. been introduced. I would like to clarify this before 19 20 you go any further. Mr. Girardi is talking about an agreement. Is that PTO 70, a participation agreement of 21 22 any other sort or is it the Master Settlement Agreement? Which is it? 23 24 MR. GRIFFIN: Your Honor, it's a participation 25 agreement that -- that Mr. Zonies had mentioned in his

opening statement. It's dated the 12th day of May, 1 2009. 2 3 THE COURT: And what is it called? 4 MR. GRIFFIN: It's called Attorney 5 Participation Agreement, Your Honor. THE COURT: And it is entered pursuant to what 6 7 pretrial order? Is it in there? I don't have a copy of 8 it yet, because you're long distance --MR. GRIFFIN: I understand, Your Honor. 9 10 THE COURT: -- so you're going to have to read it to me. You'll have to read it to me. 11 12 MR. GRIFFIN: Yes. I don't -- I don't believe 13 it was filed. I think Mr. Zonies in their papers they filed referenced it, and said because of the sensitive 14 nature of the document, that they would produce it to 15 16 the Court upon request. I assume Mr. Zonies has a copy of it there in the courtroom. 17 THE COURT: Well, it would be good, because of 18 the distance, if you read it to me, so we know that 19 20 we're talking about the same document, Mr. Griffin. MR. GRIFFIN: Very well, Your Honor. It's a 21 22 four-page document. 23 It starts, "This Attorney Participation 24 Agreement is made this 12th day of May, 2009, by and

between the Plaintiffs' Steering Committee, PSC,

25

appointed by the United States District Court for the Eastern District of Pennsylvania in MDL Docket Number 1871, and" -- and then it lists participating counsel, which on my copy is blank.

And then it says, "Whereas, the United States
District Court for the Eastern District of Pennsylvania
has appointed Rachel Abrams, Vance Andrus, Bryan
Aylstock, Marc Grossman, W. Mark Lanier, David P.
Matthews, Shannon Medley, Karen Menzies, Michael Miller,
Benedict Morelli, Dianne Nast, Tracy Rezvani, J. Paul
Sizemore, Fred Thompson and Joseph Zonies to serve as
members of the PSC to facilitate the conduct of pretrial
proceedings in the Federal actions relating to the use
of Avandia.

"Whereas, the PSC in association with other attorneys working for the common benefit of plaintiffs, the common benefit attorneys have developed or are in the process of developing work product which will be valuable in the litigation of State and Federal Court proceedings involving claims of Avandia, Avandamet and/or Avandaryl, hereinafter collectively referred to as Avandia induced injuries, the common benefit work product and; whereas, the participating counsel are desirous of acquiring the common benefit work product and establishing an amicable working relationship with

the PSC for the mutual benefit of their clients.

"Now, therefore, in consideration of the covenants and promises contained herein and intending to be legally bound, hereby, the parties agree as follows:

"This agreement incorporates by reference any order of the Court regarding assessments and incorporates fully herein all defined terms from such orders.

"Number two. This agree applies to each and every claim, case or action arising from the use of Avandia in which the participating counsel has a financial interest, whether the claim arose -- whether the claim, case or action is currently filed in State or Federal Court or is unfiled or is on a tolling agreement, hereinafter collectively be assessed cases.

"Paragraph three. With respect to each and every assessed case, participating counsel understand and agree that defendants and their counsel will hold back a percentage proportion of the gross recovery that is equal to seven percent of the gross monetary recovery, the assessment. Of that amount, four percent shall be deducted from the attorney fees and three percent from the client's share of the gross monetary recovery.

"Defendants or their counsel will deposit the

assessment in the plaintiffs' litigation expense fund. Should defendants or their counsel fail to hold back the assessment for any assessed case, participating counsel and their law firm shall deposit or cause to be deposited the assessment in the fund.

"It is the intention of the parties that absent extraordinary circumstances recognized by MDL 1871 Court order, such assessment shall be in full and final satisfaction of any present or future obligation on the part of each plaintiff and/or participating counsel to contribute to any fund for the payment or reimbursement of any legal fees, services or expenses incurred by or due to the PSC, participating counsel and/or any other counsel eligible to receive disbursements from the fund pursuant to an order of the Court regarding assessments of the fund.

"Number four. The participating counsel on behalf of themselves, their affiliated counsel and their clients, hereby grant and convey to the PSC a lien upon and/or security interest in any recovery by any client who they represent or in which they have financial interest in connection with any Avandia induced injury the full extent permitted by law in order to secure payment of the assessment. The participating counsel will undertake all actions and execute all documents

that are reasonably necessary to effectuate and/or perfect this lien and/or security interest.

"Number five. The amounts deposited in the fund shall be available for distribution to participating counsel pursuant and subject to any order of the Court regarding assessments or the fund.

Participating counsel may apply to the Court for common benefit fees and reimbursement of expenses provided that participating counsel, A, were called upon by the PSC in writing to assist in performing its responsibilities; B, expended time and efforts for the common benefit; and, C, timely submitted such time and expenses in accordance with the Court's orders or in the absence of such orders, the procedures established by the PSC.

"Number six. This agreement is without prejudice to the amount of fees or costs to which participating counsel may be entitled to in such an event.

"Number seven. Upon request of the participating counsel, the PSC will provide within a reasonable time to the participating counsel to the extent developed the common benefit work product, including access to the PSC's virtual depository; and, if and when developed, a complete trial package.

"Number eight. As the litigation progresses

and common benefit work product continues to be generated, the PSC will provide participating counsel with such work product and will otherwise cooperate with participating counsel to coordinate the MDL litigation and the State litigation for the benefit of the plaintiffs.

"Number nine. No assessments will be due by the participating counsel on any recoveries resulting from a medical malpractice claim against treating physicians.

"Number ten. Both the PSC and the participating counsel recognize the importance of individual cases and the relationship between case specific clients and their attorneys.

"The PSC recognizes and respects the value of the contingency fee agreement as essential in providing counsel to those who would not otherwise avail themselves of adequate legal representation, and it is the intent of the PSC to urge the Court to not interfere with any such agreement so long as they comport with applicable law or bar rules."

And then there's a signature block for the Plaintiffs' Steering Committee signed by Vance Andrus, and then it says participating attorneys, and it's signed by me, Your Honor, Keith Griffin.

THE COURT: And, again, that's in the year 1 2009? 2 3 MR. GRIFFIN: Yes, Your Honor, May 12, 2009. 4 THE COURT: All right. Now, perhaps, Mr. Girardi, you could tell me the agreement that you 5 referred to earlier this morning was this participation 6 7 agreement or a subsequent Master Settlement Agreement? 8 MR. GIRARDI: Your Honor, it's this agreement. It says those cases that we have in the -- it says --9 10 it's very clear that it only applies to those cases on 11 the date of this agreement that we have. It doesn't say 12 cases down the road that you're going to get or anything 13 like that. THE COURT: You're still arguing to me the 14 15 interpretation of the 2009 signature of your employee 16 there, Mr. Griffin, and I am asking you a direct 17 question as to the date of your Master Settlement 18 Agreement, sir. Mr. Girardi. MR. GIRARDI: Your Honor, could I ask Mr. 19 Griffin. 20 THE COURT: 21 Yes. 22 (Pause in proceedings.) 23 MR. GIRARDI: August of 2012 I'm informed. 24 THE COURT: And would you agree also -- I'm 25 just trying to get some facts to see if they could be

stipulated to -- that as of now in the MDL, you have a number of cases subject to an administrative suspense order that I signed on behalf of a stipulation presented by Mr. Girardi, Mr. Griffin and Mr. Zucker and Ms. Gussack. And these include a number of cases -- they go for a page and so, 20-some cases, that are presently in your settlement agreement and most of them go up to dates filed in this MDL, 2008 through 2011. Would you agree with that?

MR. GIRARDI: Yes.

MR. GRIFFIN: Yes, Your Honor.

THE COURT: All right. And these are placed in administrative suspense pursuant to the Master Settlement Agreement, correct?

MR. GRIFFIN: Correct. Well, they were placed in suspense in order to effectuate the Master Settlement Agreement.

THE COURT: Right. And a number of these cases were filed directly into the MDL by your firm, is that correct?

MR. GRIFFIN: Yes, that is true. I believe -THE COURT: And a number of those cases were
also transferred to the MDL from other District Courts
and they are included in that same list, correct?

MR. GRIFFIN: Yes, Your Honor.

THE COURT: All right. So you're really not 1 attempting to tell me that the cases in your Master 2 3 Settlement Agreement are State cases before Judge Berle, 4 correct? Although they include State --5 MR. GRIFFIN: I'm sorry, Your Honor. didn't hear that. 6 7 THE COURT: -- they -- the Master Settlement 8 Agreement includes State cases as well, correct? MR. GRIFFIN: Yes, it does. 9 10 THE COURT: And it also includes tolled cases, cases that you had agreement with GSK need not be filed? 11 12 MR. GRIFFIN: Your Honor, I don't believe -- I 13 don't believe we had any cases on a tolling agreement at the time of the MSA. 14 15 THE COURT: But you initially did? 16 MR. GRIFFIN: There initially were cases on 17 tolling agreements years before the MSA was entered 18 into. THE COURT: Well, we'll have to hear some 19 20 testimony on that if you can't agree on a date. I'm trying to figure out when some of these were filed 21 22 because it seems to be important to Mr. Girardi. 23 And is it accurate that Judge Berle is not 24 overseeing any part of your Master Settlement Agreement? MR. GRIFFIN: That is correct. He does not 25

have a role in overseeing our Master Settlement Agreement.

MR. GIRARDI: Your Honor, that isn't -- Your Honor, I have to correct that. Justice Edward Panelli, retired from the California Supreme Court, and Justice John Trotter have worked with respect to the settlement agreement, with respect to these people, as special assistants at our cost not at the Court's cost. So in that regard, there was activity from Judge Berle to permit this sort of assistance with respect to the agreements.

THE COURT: With respect to the Master Settlement Agreement?

MR. GIRARDI: With respect to --

THE COURT: Are you saying that you had private mediators? Is that what you're telling me?

MR. GIRARDI: Yes. Yes, Your Honor.

THE COURT: Other than the mediators that were appointed in the MDL?

MR. GIRARDI: Oh, yes, Your Honor. In other words, we didn't attend any mediations with the MDL. We had all of our conferences, all of our settlement conferences directly with the representatives with the defendant. We weren't -- we didn't participate in any settlements. Then with respect to Justice Panelli of

the California Supreme Court and the Presiding Justice 1 Trotter, they were then involved in the mediation 2 3 process. 4 THE COURT: And you --MR. GIRARDI: And continue to be. 5 THE COURT: -- you could choose that -- you 6 7 could choose that, right? That is not -- you weren't 8 directed to do that? You chose to do that? And you asked Judge Berle for approval? 9 10 MR. GIRARDI: Yes. 11 THE COURT: To do that? 12 MR. GIRARDI: Yes. 13 THE COURT: But as a result of your mediation, and I expect that that included GSK, so we'll hear from 14 15 them on that, Judge Berle still didn't sign the settlement agreement that came out of that, did he? 16 17 MR. GIRARDI: No, Your Honor, he did not. 18 THE COURT: All right. What else would you like to present by way of testimony or documents, Mr. 19 20 Girardi? MR. GIRARDI: Your Honor, I think that's our 21 22 story. Our story is we did it, we put out all the money 23 for it, and the agreements we signed were very limited. 24 They were not agreements that permeated all 2,800 cases. 25 THE COURT: That's the case. The respondent

rests, and we will ask the parties to present further evidence. So I would like to know who would like to proceed first?

MR. ZONIES: Your Honor, if I could have a minute to consult with my counsel --

THE COURT: Yes.

MR. ZONIES: -- my fellow counsel.

(Pause in proceedings.)

MR. ZONIES: Your Honor, our first witness had to run to the -- he'll be right back.

THE COURT: All right. Let me ask GSK, you're here as an interested party, and of course, the second matter before the Court is your motion. So we asked you to be present. The Court was interpreting affidavits and other documentation that had been submitted earlier as to the state of the MDL record, cases that were filed here initially, cases that were removed here, that were part of the Girardi Keese firm.

Did you agree or disagree with any of those statements? Because I really did take them from Mr. Zucker's affidavit.

MS. GUSSACK: No, Your Honor. I believe that both Mr. Griffin and the affidavit accurately states, cases were filed directly in the MDL, some were transferred here, others were participating in the

Master Settlement Agreement with Mr. Girardi, with other lead plaintiffs' counsel's name.

THE COURT: All right. Now, can you tell me if there were any tolling agreements with the Girardi firm cases --

MS. GUSSACK: I can't --

THE COURT: -- and claims?

MS. GUSSACK: -- I can't say with certainty, Your Honor. I believe at the outset that there were tolling agreements and then they were -- became filed claims.

I would clarify, Your Honor, that we are an interested party to the extent that one of the issues in the Master Settlement Agreement requires that we address the issue of the holdback of the common benefit fee and that's been a point in contention. I believe Mr.

Griffin quite accurately states Judge Berle has no role in overseeing the Master Settlement Agreement. Justice Trotter and Justice Panelli are private mediators at JAMS.

They were selected by Mr. Girardi to help him assist in the allocation and implementation of his Master Settlement Agreement. There is no effectuating order by Judge Berle as to that assignment that Mr. Girardi made of these two private former Justices.

THE COURT: And to clarify, GSK did not mediate the cases before either of those retired Justices?

MS. GUSSACK: No, Your Honor. They were not mediators. We negotiated directly with Mr. Girardi, and Justice Trotter and Justice Panelli were appointed by Mr. Girardi to assist him in effectuating the settlement, to review claims and to allocate, as I understand it.

But there is no Court that has any role in the oversight, implementation or effectuation of this settlement agreement, and it's why we came here because we believe that the Court does have an interest for a variety of reasons we can discuss after the common benefit phase.

THE COURT: All right. Then I have to ask you, Mr. Girardi, by what notion do you state that Judge Berle appointed the JAMS mediators to what is an internal process, as I understand it, between you and your clients, an administrative process if you will, when you have so many clients as you did?

MR. GIRARDI: As Your Honor I think -- you know, Your Honor, I think that's accurate. We advised Judge Berle that we were going to use Justice Panelli and Justice Trotter because of the complicated nature of

the settlement not only with respect to assistance in any sort of negotiations that came up, but also to make sure the clients were treated fairly and felt that they were treated fairly.

So I would like to correct myself, Your Honor. We did not have him sign a formal, "I hereby appoint," but we did advise the Judge and he thought this was a terrific idea. And we could have given him the document to appoint them to assist in the case, but we did not.

THE COURT: But he did not --

MR. GIRARDI: But that's a good point.

THE COURT: -- but he did not even attempt to approve it formally. It's a heads-up, and that's about what it is, because you at all times have the absolute right to hire whoever you chose from the private sector to administrate the claims within and against your own clients, because, obviously, when you have aggregate settlements, that's necessary, isn't it?

MR. GIRARDI: Well, I think that's -- I think that's true. But in light of the fact that there could have been issues that would be raised with respect to the settlement agreement, we wanted to make sure that Judge Elihu Berle was very comfortable with the fact that Presiding Justice Trotter and Justice Panelli were involved in the situation.

THE COURT: Except that --

MR. GIRARDI: And --

THE COURT: -- except that Judge Berle doesn't have anything to do with your settlement agreement. He didn't sign it, did he?

MR. GIRARDI: No.

THE COURT: He wasn't going to sign it, was he?

MR. GIRARDI: Well, he only had something to do with the settlement agreement insofar as all these cases were under his jurisdiction, and if we made a representation to him that we think we have an agreement with respect to settlement, et cetera, it became his business with respect to the settlement. So I don't think we could --

THE COURT: Well, if you say all of his cases, Mr. Girardi, you can't include the Federal cases, because by my order, they can't be subject to a State Judge's coordination or authority, and Judge Berle who worked very closely with me throughout the MDL really never breached that particular term of my orders.

So I'm not sure what's in your mind, but I have to stop it right there, because you can't argue that he was supervising your litigation, your mediation, when GSK wasn't part of it. They weren't part of it,

were they? You hired JAMS to do private administration of the claims and how you would parse out the money that GSK was willing to give you lump sum between your various clients, is that correct?

MR. GIRARDI: Your Honor, not quite. Justice Panelli and Justice Trotter were very much engaged in the discussions with the defendant in terms of resolving issues that came up between us and them. So they -- they know the defendants by their first name in terms of going back and forth with respect to issues and so forth. So that did take place.

THE COURT: Are you telling me --

MR. GIRARDI: But you're right about the Federal --

THE COURT: Wait a minute. Are you telling me that your negotiation with GSK went through JAMS as a mediator when -- before you signed a Master Settlement Agreement? Is that what you're telling me?

MR. GIRARDI: Your Honor, I don't -- I don't think I quite understand the Court's question. I'm certainly not trying to misrepresent anything. We entered into --

THE COURT: I'm trying to clarify this, Mr.

Girardi, because I think we only have so many minutes

left in this -- in this proceeding, and I'm going to ask

you one more time. Before you --

MR. GIRARDI: All right.

THE COURT: -- signed a Master Settlement Agreement, who negotiated that with GSK?

MR. GIRARDI: We did.

THE COURT: Did you go to any mediator whatsoever before that Master Settlement Agreement was signed?

MR. GIRARDI: Your Honor, I think we did, because it took some time for the Master Settlement Agreement. But, Your Honor, I'm not going to stake my political and legal reputation on that, Your Honor. I can't answer. But there was a long period of time between the time the negotiations started till the time the thing ended out.

And did we actually sit down paragraph by paragraph with any of those people? No, I don't think so. On the other hand, did we discuss the concepts with Justice Panelli and Justice Trotter before the matter was consummated? The answer to that question, Your Honor, is yes. And did Judge --

THE COURT: And I have asked you repeatedly to tell me if the mediators were involved with GSK. I care not what you used them for unless it was between you and GSK. That is what I am asking you, sir. I don't know

why that's complicated. 1 MR. GIRARDI: Your Honor, there was a lot of 2 3 communication with GSK and Justice Trotter. 4 THE COURT: Was there --MR. GIRARDI: As a matter of fact, the last 5 conversation -- the last conversation --6 THE COURT: Okay. That's enough. 7 8 MR. GIRARDI: -- took place a week ago. THE COURT: That's enough. 9 10 MR. GIRARDI: I'm sorry. THE COURT: All right. That is not 11 12 negotiation. That is clarifying who is claiming what 13 I'm too well versed in the actual MDL work here injury. to believe anything else. So, please, choose your words 14 carefully, Mr. Girardi. You don't want to make a 15 16 mistake here and neither do I, quite frankly. 17 All right. Present your witness, Mr. Zonies. 18 MR. ZONIES: Thank you, Your Honor. Call Mr. Vance Andrus to the stand, Your Honor. 19 20 COURTROOM DEPUTY: Please raise your right hand and place your right hand on the Bible. 21 22 VANCE R. ANDRUS, PETITIONER'S WITNESS, SWORN. 23 COURTROOM DEPUTY: Please state your full name 24 for the record.

THE WITNESS: Good morning.

43 1 **DIRECT EXAMINATION** BY MR. ZONIES: 2 3 Good afternoon, Mr. Andrus. Good afternoon. 4 Could you please state your full name for the 5 record. 6 7 My name is Vance Robert Andrus. Α 8 Mr. Andrus, we're going to try to move through this rather quickly, but first of all, what was your role, if 9 10 any, in the Avandia litigation? Yes, sir. I was appointed by this Court to be a 11 Α 12 member of the Plaintiffs' Steering Committee. I had the privilege of serving as the co-lead counsel along with 13 Bryan Aylstock in that role until such time as the Court 14 15 ultimately replaced us with other members, and then I continued to serve as a member of the PSC Advisory 16 17 Committee from that date to this. I also served on and continue to serve on the 18 PSC Fee Committee. 19 20 Mr. Andrus, I'd like to hand you an exhibit. MR. ZONIES: May I approach the witness, Your 21

Honor?

THE COURT: You may.

BY MR. ZONIES:

22

23

24

25

Mr. Andrus, I've handed you a document. It's

actually from the -- Document Number 108 from this MDL's docket. Do you recognize that document?

A I do.

Q And what is that?

A For the benefit of Mr. Girardi who may not have a copy of it, this is the original order of this Court. I suspect the Court could take judicial notice of it, but it's Document 108 filed in MDL 1871, dated 9th, April, 2008. It is the original order under which the Court appointed the original Plaintiffs' Steering Committee in this MDL.

MR. ZONIES: Your Honor, I'd move admission of Exhibit 1 and ask the Court to take judicial notice that it is, indeed, Document 108 from the Court's docket, the original order appointing the Plaintiffs' Steering Committee in MDL Number 1871, In re Avandia Marketing Sales Practices.

THE COURT: Those requests are approved. The Court has pulled the very same order from the docket this morning, and it is identical. We will take judicial notice of my appointment to those members of the Plaintiffs' Steering Committee, one of which is Number 12, J. Paul Sizemore, Esquire, Girardi Keese Law Firm.

(Petitioner's Exhibit 1, Document 108 from MDL

Number 1871, is admitted into evidence.)

MR. ZONIES: Thank you, Your Honor.

BY MR. ZONIES:

Q Mr. Andrus, what's the date of the order appointing

Mr. Sizemore of the Girardi Keese firm to the PSC?

A The date was April 9th, 2008.

Q Prior to that appointment to the PSC, Mr. Andrus,

did indeed the PSC, who ultimately became the PSC

members, perform any work to further the Avandia

litigation prior to this appointment?

A They did. If I may explain, in May of 2007, the Nissen article which first discussed the relationship between Avandia and an increased risk of heart attacks was published.

A substantial number of attorneys selforganized under the leadership of myself and Mr.

Aylstock, and that included Mr. Sizemore, our working
group worked independently of but also directly with GSK
prior to the creation of the MDL by the JPML, subsequent
to the creation and actually negotiated with GSK certain
terms involving, for example, plaintiff fact sheets,
prior to the date of this order.

So we started working in approximately July or August of 2007.

Q And during the period of time where there was work

- before Mr. Sizemore was appointed to the PSC, Mr.
- 2 Andrus, was he at that time also with the Girardi Keese
- 3 firm as far as you know?

7

8

9

10

13

14

15

16

17

18

- 4 A Yes, to my knowledge.
- Q What was your understanding of Mr. Sizemore's position with the Girardi Keese firm?
 - A Mr. Sizemore took the position he was a partner. He freely acknowledged he was not a shareholder or equity partner, but he presented himself as a partner of the firm. Whether or not he was, I don't know.
- Q You had no reason to doubt Mr. Sizemore was indeed a partner with the firm?
 - A I had no reason to doubt anything. He filed his application with firm stationery and on firm letterhead, and he acted at all times as though he was authorized to -- to do work and represent the firm.
 - Q Did he appear to have the apparent authority to bind the firm?
 - A I think so.
- MR. ZONIES: May I approach the witness, Your
 Honor?
- 22 THE COURT: You may.
- BY MR. ZONIES:
- Q Mr. Andrus, I've handed you Exhibit 2. It's a document entitled, Attorney Participation Agreement, and

Mr. Andrus - Direct

I believe the terms of this agreement were read in whole this morning. Do you recognize this document?

- A I do. This is the document, Document Number 2 you've handed me is the document that Mr. Griffin read to the Court and which bears his signature and my signature.
- Q And what is your understanding of what this document is?
- A Well, this is an Attorney Participation Agreement.

 It's dated May 12th, 2009, which I think is subsequent to the date that Mr. Sizemore departed from Girardi Keese, so this document was signed by Keith Griffin as a representative of Girardi Keese afterwards.

Just two notes. One, I think I've seen a copy of this document where on page one it has Mr. Griffin's name penciled in, inked in, and I've seen a version of it without it. I don't know, Mr. Griffin, if the one --which one you read, whether it had your name inked in on the same page or not. The one you've given me does not have his name on it, but it has both his signature and his name printed on the last page, and there was a reason for that.

- O And what was the reason for that?
- A In May of 2009, the Plaintiffs' Steering Committee held a highly confidential full-day seminar in which we

were going to discuss strategy and tactics for use in connection with the ongoing litigation against GSK that was to be held here in Philadelphia as I recall. I was in charge and had directed that the participation agreement be prepared, and one be prepared for each attorney who -- who declared that they would attend, but I wanted their names typed on because attorneys are notorious for their signatures.

And I'd already had one bad episode of that at an earlier meeting, and so I had one printed. I had Mr. Aylstock's secretary print one for each person. This is the one that Mr. Griffin -- was printed for Mr. Griffin and which Mr. Griffin signed when he and Mr. Girardi both attended that -- that seminar.

MR. ZONIES: If I haven't moved for admission of Exhibit 2, Your Honor, I do so now.

THE COURT: Any objection?

MR. GIRARDI: No. No objection.

THE COURT: Thank you.

BY MR. ZONIES:

Q Mr. --

THE COURT: Number 2 is admitted.

MR. ZONIES: Sorry, Your Honor.

(Petitioner's Exhibit 2, Attorney

Participation Agreement, is admitted into evidence.)

BY MR. ZONIES:

- Q Mr. Andrus, could you please read the first paragraph, paragraph number one, of the participation agreement?
- A The paragraph numbered one?
- O Yes.
 - A The paragraph numbered one says, "This agreement incorporates by reference any order of the Court regarding assessments and incorporates fully herein all the defined terms from such orders."
- Q It -- was the Court's order, PTO 70, about assessments?
 - A It was indeed Pretrial Order Number 70. It was signed 26th, August, 2009, and addresses the issue of common benefit fees and assessments.
 - Q Now, we haven't heard from Mr. Girardi about Mr. Griffin's position with his firm. Do you understand that Mr. Griffin is an associate or intern with Girardi Keese?
 - A Mr. Griffin to my understanding certainly is an associate -- he was then. He may now be a partner. If so, congratulations, Keith, but -- and, if not, Girardi, you ought to make him a partner. He's a good man.

MR. ZONIES: Your Honor, may I approach -THE COURT: Yes, you may.

1 MR. ZONIES: -- the witness? Thank you.

BY MR. ZONIES:

2

3

4

5

6

7

8

9

10

11

12

13

16

17

18

19

20

21

22

23

24

25

Q Mr. Andrus, I've handed you what has been marked as

Exhibit 3. Could you describe what Exhibit 3 is,

please?

A Exhibit 3 is a letter from me as Chair and lead

counsel of the Plaintiffs' Steering Committee dated

August 31st, 2009, to Ms. Nina Gussack with Pepper,

Hamilton, which discusses certain aspects of PTO 70.

MR. GIRARDI: No objection.

BY MR. ZONIES:

Q And what was the date of that letter?

A August 31st, 2009.

MR. ZONIES: Your Honor, I'd move admission of

Exhibit 3.

THE COURT: Any objection?

MR. GIRARDI: I have no objection.

THE COURT: Thank you. Number 3 is admitted.

(Petitioner's Exhibit 3, letter dated 8-31-09,

is admitted into evidence.)

BY MR. ZONIES:

Q Mr. Andrus, what was the purpose of Exhibit 3?

A Under PTO 70, cases which were subject to an

assessment, a seven percent assessment, were defined as

"covered cases" and there were various ways cases could

be considered covered cases. For example, all cases of all the PSC members were covered cases, but there were other ways.

One of the provisions of PTO 70 provided that, while not required to do so, the PSC could from time to time send to GSK a letter listing those cases which it believed -- cases or attorneys or law firms which it believed to be covered by PTO 70. GSK had an interest in that because under PTO 70, GSK is jointly and severally liable with whomever owns, owes the assessments if there is a -- if there is a determination by this Court that the assessment is due.

So it was an accommodation to GSK that I sent this letter in which I say that a member of each of the firms listed on Exhibit A is either a member of the MDL PSC or has signed either the protective order or the participation agreement.

The participation agreement we're referring to is your Exhibit 2, and the protective order is an endorsement to PTO 10 which sought to protect as confidential all of the documents that were delivered in the litigation, and which by its own terms, applies to all PSC members and their law firms.

Q It's --

A So I was sending them a list of lawyers and law

firms.

1

2

3

4

5

6

7

8

9

10

11

12

13

16

17

18

- Q Okay. And it's fair to say that this was your representation to GSK that these attorneys were bound by PTO 70 and needed to pay the assessment for all covered claims, correct?
- A Yes, but with one additional point. As the letter points out, it speaks for itself, but as it points out, I copied every one of these law firms through their managing partner or their PSC member so that there -- there would not be a dispute later. Here's -- here's a copy. If you have a problem, contact us. And --
- Q And by that, you're referring to that second paragraph that begins with, "By copy"?
- A Yes, "By copy, we are informing all counsel listed on Exhibit A of this communication."
 - Q And what's the next sentence, sir?
 - A "Should any of them disagree with our designation of their cases as covered claims, we invite them to contact me to discuss the matter."
- Q Thank you. And if you turn to the list that is attached as Exhibit A.
- 22 A Okay. I've got it.
- 23 Q Is Girardi Keese one of the firms on that list?
- 24 A Yes, sir.
- 25 Q Whereabouts, in the middle of that first column,

53

1 right?

- A Yes, sir, on the left-hand side in the middle of the column.
- Q Would it have been your habit and practice in your business then to have forwarded this to Girardi Keese to see if they had objection to their being listed as someone who was obligated to pay the assessment on their cases?
 - A Yes, sir.
- 10 Q Do you believe you did so?
- 11 A I know I did so.
- 12 Q Did you ever receive any objection from Mr. Girardi?
- 13 A No.

- 14 Q Until recently?
- 15 A Not until these proceedings.
- MR. ZONIES: May I approach, Your Honor?
- 17 THE COURT: Yes.
- 18 BY MR. ZONIES:
- 19 Q Mr. Andrus, I've handed you what's been marked as
- 20 Exhibit 4. Could you describe that document, please?
- 21 A Exhibit 4 is another letter, virtually identical to
- 22 Exhibit 3. Exhibit 3 was dated August 31st, 2009.
- 23 Exhibit 4 is yet another letter I sent to GSK, care of
- Ms. Gussack, dated September 21st, 2009, to -- I mean,
- it may be -- yes, it's exactly the same, and it has a

Mr. Andrus - Direct

- different Exhibit A because it may have additional or different PSC members or counsel that we think their cases were covered.
- Q And is Girardi Keese listed indeed on Exhibit A for that document, that letter as well?
- A Let me look. Yes. And you can see Exhibit A on

 Number -- Exhibit Number 4 is laid out differently -- in
 a different manner column-wise than Exhibit 3, but, yes,
 they are listed.
- Q And to your knowledge, did you ever receive any notice or objection from Mr. Girardi or the Girardi Keese firm about whether or not they believed they owed the assessment at that time?
- A I did not receive any such objection.
- Q And, Mr. Andrus, because you didn't receive any objection, did the PSC continue to share information to your knowledge with the Girardi Keese firm?
- A Indeed they did, both before and after Mr. Sizemore departed. While Mr. Sizemore was an employee of Girardi Keese, he was Chair of our Science Committee. He was our head science guy at that time and was involved in all discovery at -- and had access to all documents and all work product.
- MR. ZONIES: May I approach, Your Honor?
 THE COURT: Yes.

1 BY MR. ZONIES:

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Q Mr. Andrus, I've handed you a document marked as

Exhibit --

A -- 5.

MR. ZONIES: I move admission of Exhibit 4, Your Honor, the letter from Mr. Andrus dated 9-21-09, to, amongst others, Mr. Girardi and Girardi Keese.

THE COURT: Is there any objection?

MR. GIRARDI: No, Your Honor.

THE COURT: Thank you. 4 is admitted.

(Petitioner's Exhibit 4, letter dated

September, 2009, is admitted into evidence.)

BY MR. ZONIES:

Q Mr. Andrus, I've handed you what's been marked as
Exhibit 5. It is Document Number 495 from this Court's
docket in the In re Avandia MDL, and it's entitled
Pretrial Order Number 70. Do you see that?

A I do.

Q Mr. Andrus, if you could turn to page five of PTO 70, please.

A I have.

Q Page five of PTO 70 has section three entitled covered claims, is that correct?

A That's correct.

Q And what do you understand a covered claim to mean?

ase 2:07-md-01871-CMR Document 3963 Filed 04/17/14 Page 56 of 107 Mr. Andrus - Direct Is that a claim upon which an assessment is otherwise 1 due? 2 3 Α It is. And covered claims, according to Exhibit 5 include, 4 for example, under 3A, all claims in cases where the 5 attorney has signed a participation agreement, is that 6 7 right? 8 No. Actually, A goes further than that. Under paragraph 3A, it's "all claims now or hereafter subject 9 10 to the jurisdiction of this Court." It's not just limited to present claims. 11 12 It's, "all claims now or hereafter which are," and then there are three things, "subject to an MDL supervised 13 14 15

settlement, claims on tolling agreements, and all claims in which a PSC member has an interest."

So there, for example, includes claims on tolling agreements and those in which a PSC member has a financial interest, correct?

16

17

18

19

20

21

22

23

24

25

That's correct. And under paragraph B, it even -it even applies to claims "filed in another jurisdiction provided, either one, the attorneys are subject to the protective order, or, two, the attorneys have signed the participation agreement."

And part of that is the attorneys are either members of the PSC or have signed the participation

1 agreement.

Q Then by participation agreement, you mean the Exhibit -- an example that is Exhibit 2 signed by Mr. Griffin, correct?

A That's correct. That -- the agreement that Mr.

Griffin signed -- excuse me -- is actually attached to

PTO 70 as an exhibit. So, in other words, when the

Court signed PTO 70, the Court created the participation

agreement.

And the distinction between them is this. A confidentiality order protects the confidentiality of certain information. That's PTO 10. PTO 70 declares that certain claims are covered -- it speaks for itself -- and those claims are subject to an assessment.

One of the ways a claim becomes a covered claim is if the claim is represented by an attorney who signed the participation agreement. So what's the participation agreement? Well, the participation agreement is a private agreement -- again, it speaks for itself -- but it's a private agreement between the parties, the Plaintiffs' Steering Committee and the attorney signing it in which, in return for subjecting his clients' claims to PTO 70, the attorney acquires access to all work product of the Plaintiffs' Steering Committee.

ase 2:07-md-01871-CMR Document 3963 Filed 04/17/14 Page 58 of 107 Mr. Andrus - Direct 58 MR. ZONIES: May I approach the witness, Your 1 Honor? 2 3 THE COURT: You may. MR. ZONIES: Move for admission of Exhibit 5, 4 Your Honor. 5 THE COURT: Any objection? 6 7 MR. GIRARDI: No objection. THE COURT: Exhibit 5 will also be admitted. 8 Thank you. 9 10 (Petitioner's Exhibit 5, Pretrial Order Number 70, is admitted into evidence.) 11 12 BY MR. ZONIES: 13 Mr. Andrus, I've handed you a document that's -- I'm marking here as Exhibit 6. Do you have that in front of 14 15 you? 16 Α Yes, sir. 17 Exhibit 6 is Document Number 2740 in this Court's 18 docket for the Avandia litigation. It's dated 10-9-2012. 19 20 Yes, sir. Α What do you understand Exhibit 6 to represent? 21

Exhibit 6 is the stipulation and order to place in

administrative suspense certain cases which were on the

which were on the active docket in this MDL as of that

docket, which cases were filed by Girardi Keese and

22

23

24

25

Α

date. So they're being suspended pursuant to a Master

Settlement Agreement Girardi Keese entered into with

GSK.

Q And do you see the numbers on some of these cases, 2:08 --

A Yes.

Q -- 2:11 or 11. What do you understand those 08 and 11 to mean?

A The Court allocates docket numbers by the date on which they were filed, and so those cases were filed in 2008 through 2011. That's my understanding of the Court's numbering system.

Q And then it's signed on the second page, the stipulation and order to place in administrative suspense, is that right?

A That -- yes.

Q And what's the -- what is the -- is the Girardi Keese firm listed on that signature block?

A It is.

Q And what's the date of that signature of either Mr. Girardi or Mr. Griffin in this stipulation filed in this MDL for the 20-plus cases that were active in this MDL from 2008 through 2011 while these PSC members were working?

A It's 10-4-12, October 4th, 1912 -- I mean, 2012.

Mr. Andrus - Direct 60 MR. ZONIES: And, Your Honor, I'd move 1 admission of Exhibit 6 and ask the Court to take 2 3 judicial notice of it as part of the Court's docket. THE COURT: Any objection? 4 MR. GIRARDI: No objection, Your Honor. 5 THE COURT: All right. We will grant those 6 7 requests. (Petitioner's Exhibit 6, stipulation and order 8 dated 10-4-12, is admitted into evidence.) 9 10 BY MR. ZONIES: 11 Mr. Andrus, do you believe that Mr. Girardi and 12 Girardi Keese should pay an assessment on the cases that 13 they settled in the Avandia litigation? I do. Pursuant to PT --14 15 MR. GIRARDI: Well, I object -- I object to 16 the question, Your Honor. That isn't his decision. 17 It's yours. THE COURT: Mr. Zonies. 18 MR. ZONIES: Your Honor, actually, I'll 19 20 withdraw that question and keep putting on some more evidence. I'm finished with this witness for the time 21 22

being.

THE COURT: Very well. Thank you.

THE WITNESS: Thank you.

23

24

25

THE COURT: You're welcome.

Mr. Andrus - Cross

61

Oh, I'm sorry. Did you have any cross-1 examination? 2 3 MR. GIRARDI: Yes, Your Honor. THE COURT: Okay. I'm sorry. You were going 4 to remind me to do that. I'm aware of the time. Don't 5 I have a 2:00 sentencing? Do I have a sentencing? At 6 7 3:00? Okay. We have some time. Proceed please. 8 MR. GIRARDI: Thank you very much, Your Honor. CROSS-EXAMINATION 9 10 BY MR. GIRARDI: Sir, those 20 cases you just talked about, those 11 were the only cases that were addressed on that 12 particular document, right? 13 Yes. But the document speaks for itself, but I 14 think that's a fair characterization, Mr. Girardi, and 15 that document only refers to those cases. 16 17 All right. 18 THE COURT: And there's 25, Mr. Girardi. BY MR. GIRARDI: 19 20 It doesn't refer to the -- I'm sorry. THE COURT: There's 25 -- there's 25. 21 22 BY MR. ZONIES: It does not -- it does not include the 2,700 cases 23 24 that were pending in the California Court, that particular document? 25

Mr. Andrus - Cross

62

- A No. The particular -- that is --
- Q Okay.

1

- 3 A -- pardon me. You asked a double negative. Let me
- 4 -- let me try to answer it. The document you're
- 5 referring to refers only to the 25 cases listed on the
- document and to no other cases, that is correct.
- 7 Q All right. Thank you very much. Then the other
- 8 document that Mr. Griffin signed --
- 9 A Yes.
- 10 Q -- only applies -- only applies by its terms to
- 11 those cases that the firm has a financial interest at
- this time, at the time of the signature, isn't that
- 13 true?
- 14 A Well, Mr. Girardi, your objection to Mr. Zonies'
- prior question probably applies. That's ultimately
- something for the Court to decide. I don't read -- you
- and I read -- read that document differently. I read
- 18 the participation agreement that Mr. Griffin signed,
- 19 together with PTO 70 and PTO 10, I read all three
- 20 together. And read together --
- 21 Q All right.
- 22 A -- they -- if I may, read together, I think it's a
- fair interpretation to say, no, it applies to all cases,
- and the reason for that, if I may explain, is because
- 25 you --

MR. GIRARDI: Well, I'll object -- I'll object to that. He's answered the question.

THE COURT: Well, actually, you did ask him to answer the question, and he's explaining his answer.

Overruled. You may answer, Mr. Andrus.

MR. GIRARDI: Okay.

THE WITNESS: The reason for that, Your Honor, is the bell -- just as the bell can't be unrung, once one shares common benefit -- a common benefit work product with another, the other then knows and understands. I disagree with Mr. Girardi that he didn't use our stuff because I think he did and I think our evidence can demonstrate that.

But the point is that Mr. Girardi himself, Mr. Griffin himself, attended strategy conferences in which there was a full explication of all the trial strategy, tactics, documents. They were provided copies of all of our documents, and that enures to the benefit of every client that he has, not only those in 2008 or 2009, but every one to the very last one. And that, Mr. Girardi, is why I respectfully disagree with your interpretation. BY MR. GIRARDI:

Q Well, sir, the document says, by its terms, and the only document that you have a signature on of Keith Griffin says that -- it provides that there is an

Mr. Andrus - Cross

interest only in those cases that the firm has a financial interest, and the date of that document was the 12th day of May, 2009. Isn't that what it says, sir?

- A No, that's not what it says. Paragraph --
- Q Okay. Would you do this for me, then --
 - A Okay. Let's read it.
 - Q -- would you -- would you read paragraph two --
- A Yes. Okay.

- Q -- to her Honor?
 - A I will. "This agreement applies to each and every claim, case or action arising from the use of Avandia, in which participating counsel has a financial interest, whether the claim, case or action is currently filed in State or Federal Court or is unfiled or is on a tolling agreement."
 - It doesn't say anywhere, as of this date. It doesn't refer to, in the future, in the past.
 - Q Now, sir, I think you read the -- you read what I asked you to read.
- 21 A Okay.
 - Q The fact of the matter is that this doesn't apply to cases that somebody is going to get the next year, according to its very terms?
- \parallel A I disagree, and I'd like to explain why.

Mr. Andrus - Cross

Q Okay. Well, that's all right. You disagree; that's good enough. Did --

A I --

THE COURT: Mr. Girardi --

BY MR. GIRARDI:

Q -- did you make the 105 --

THE COURT: -- Mr. Girardi.

MR. GIRARDI: I'm sorry, Your Honor.

THE COURT: You are debating --

MR. GIRARDI: Yes, Your Honor.

THE COURT: -- you are debating with the witness. And if you are going to ask questions like that, then the witness gets to debate back. You may answer.

THE WITNESS: Mr. Girardi, regardless of our debate about whether the participation agreement, under its own words, applies to only present or present and future cases, regardless of that, PTO 70 trumps it, and PTO 70 applies to all Avandia claims now or hereafter, subject to the jurisdiction of this Court.

And these claims are subject to the jurisdiction of this Court, because Mr. Griffin signed the participation agreement, because Mr. Sizemore was a PSC member, and was a PSC member from April until the following January -- I mean, was a member of your firm,

and because of Pretrial Order Number 10.

I -- I'm sorry, Your Honor. I don't want to debate with Mr. Girardi about that. We just have a disagreement about what it means.

BY MR. GIRARDI:

- Q The \$200,000 that apparently Sizemore was entitled to, was never paid to our firm, isn't that correct?

 A That's incorrect. Your firm rejected the payment.

 Your firm submitted common benefit time, at least through the time that Mr. Sizemore left. That time, ultimately, was adjudicated and was subject to an order of this Court, awarding your firm a common benefit fee of \$200,000, the check for which you did return and said words to the effect, we don't want this or this -- this isn't ours or please, keep this money. And you sent the money back.
- Q And then, your common benefit fees were -- amounted to \$17,150,000?
- A I -- well, I don't --
- 20 Q Did they or not?
 - A No, I -- I don't recall it being that big, and I wish it was. I don't recall it being that big a number, but the award -- no, I don't think my award was that amount. I think it was less than that. I think it was still much larger than the one you're talking about, and

Mr. Andrus - Redirect 67 it's contingent in part on the ultimate collections, 1 which the Common Benefit Assessment Fee Fund acquires. 2 3 So the answer is, no, I haven't been paid \$17 million. 4 Did you put out 14 million in costs in the case? Well, I don't know. Did you -- our Plaintiffs' 5 Α Steering Committee, I believe --6 7 Q No, sir, you. 8 Α Me, personally? No. 9 Q Yes. 10 Α No. MR. GIRARDI: I have nothing further, Your 11 12 Honor. Thank you. Any redirect? 13 THE COURT: MR. ZONIES: Just one question, Your Honor. 14 15 I've made the mistake of saying that. 16 REDIRECT EXAMINATION 17 BY MR. ZONIES: 18 Mr. Andrus, to your knowledge, does the allocated amount for the Girardi Keese firm remain in trust, 19 20 awaiting Girardi Keese's decision to -- whether or not he would like to change his mind? 21

22

23

24

25

Α

It does.

The fund administrator has placed that

money in suspense, and he does -- well, he -- he is

simply holding it until there is a resolution by this

Court as to whether or not -- I don't know -- as to the

THE WITNESS: K-A-U-F-M-A-N.

Good afternoon, Mr. Kaufman.

DIRECT EXAMINATION

Could you please describe for the Court what you do

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

BY MR. ZONIES:

Good afternoon.

and with whom you do it?

Q

A Sure. I am a partner with the law firm Heard Robins Cloud. I am out of the Santa Fe, New Mexico office. My partner, Bill Robins, was a member of the Plaintiffs' Steering Committee in the Avandia litigation. Bill and I worked together on the Avandia litigation from 2011, from the time Bill was appointed to the PSC, through the time that we settled our Avandia cases in January of 2012.

That settlement came about shortly before we were ready to try our first bellwether case in the California JCCP.

- Q So, you -- Heard Robins and you, personally, worked on cases that were, indeed, in the California JCCP, along with some of Mr. Girardi's cases, is that right?
- A That's right.
- Q Were you actively involved in that California litigation?
- A We were.

- Q You heard testimony perhaps today from Mr. Girardi, under oath, that he did not use or utilize any of the MDL work product or experts or documents, other than receiving those documents that were generated, and the work done here in the MDL, have you heard that testimony today?
- A I have.

- Q Do you agree with that?
- A I don't.

Q Why not?

A Starting in the middle of 2011, there were a number of cases that were chosen as trial pool cases in the California JCCP. Our firm represented clients in that trial pool, as did Mr. Girardi's firm. When the cases were chosen as trial picks, all of those cases, and all of those plaintiffs' firms worked together on all of those cases.

All of those cases faced summary judgment motions from the defendant, and together, all of the plaintiffs' lawyers worked together to oppose those summary judgment motions. In opposition to those summary judgment motions, all of the plaintiffs' lawyers utilized MDL work product that had been developed since you and Mr. Andrus and Mr. Aylstock and everyone else had begun the MDL shortly in the middle of 2007 and all of the work product that had been developed up until that point.

And so when the summary judgment motions came up in California, the pleadings very much relied upon the evidence that was developed by the MDL, and our firms collectively filed pleadings relying upon that work product.

Mr. Kaufman - Direct

- Q And by our firms, who do you mean?
- A The Heard Robins firm, the Girardi firm, as well as other firms that had represented clients in the California JCCP, as well as clients in the MDL.
- Q And you were personally involved in these litigations in California?
- A We were, yes.

- Q Do you know, for example, whether or not the Girardi Keese firm relied upon experts that had been developed completely in the MDL?
- A Yes. We relied upon a handful of experts, in particular, in order to oppose the summary judgment motions that were filed by GSK. There were three experts who we used to file declarations in California in support of our summary judgment oppositions.

Those experts were Dr. Suzanne Parisian, Dr. Elliot Brinton and Dr. Nicholas Jewell. They filed declarations in our cases in California, and we, in opposition to the summary judgment motion, cited and relied upon those declarations in support of our oppositions.

- Q And Dr. Jewell is a biostatistician, is that right?
- A He is, yes.
 - Q And Dr. Jewell was the biostatistician that this Court held <u>Daubert</u> hearings on, and he came and he

```
Case 2:07-md-01871-CMR Document 3963 Filed 04/17/14 Page 72 of 107
                            Mr. Kaufman - Direct
                                                                   72
         testified. And he was able to get past <u>Daubert</u>
 1
         challenges in the MDL?
 2
 3
             Yes, that's correct.
             The same with Dr. Elliot Brinton?
 4
         0
 5
         Α
             Yes.
             Dr. Elliot Brinton testified before this Court in
 6
         Q
 7
         the <u>Daubert</u> hearings?
 8
         Α
             That's right.
             And the same with Dr. Parisian, as well, correct?
 9
         Q
10
         Α
             Yes.
                   MR. ZONIES: May I approach, Your Honor?
11
12
                   THE COURT: You may.
13
                    (Pause in proceedings.)
         BY MR. ZONIES:
14
15
             Mr. Kaufman, I have handed you what's been marked as
         Exhibit 6 -- 7?
16
17
                   MS. NAST: 7.
18
                   THE COURT: 7.
         BY MR. ZONIES:
19
20
             Exhibit 7. Do you see that document?
         Q
             Yes.
21
         Α
             And Exhibit 7, actually, the lead page on it says,
22
         Q
         Exhibit C, is that right?
23
```

And what do you -- can you describe, please, what

24

25

Α

Q

Yes.

Exhibit 7 is?

A Exhibit 7 is the plaintiffs' exhibit list that was filed in a case captioned Nancy LeVoise (ph) -- I don't know if I'm pronouncing that correctly -- versus GSK.

- Q And can you describe, please, what that document is?
- A This is an exhibit list that was filed by the plaintiffs in the LeVoise versus GSK case. It lists some 2,300 or 2,400 documents as exhibits in that case.
- Q Do you know who counsel was on the LeVoise case?
- A It was the counsel for the Girardi Keese firm.
 - Q This is the Girardi Keese client in the JCCP?
- A It's one of their clients, yes.
 - Q And there -- as you pointed out, there are over 2,395 exhibits listed on this -- on this exhibit list for that trial, is that right?
- 16 A Yes.
 - Q And the -- did you have any role in creating this exhibit list?
 - A Yes. This document took some years off of my life. This was an exhibit list that began in the MDL. At the time when the MDL prepared it, it had some 1,000 exhibits on it. And in the time that Bill Robins and I were working in the MDL, as well as in California, we added approximately another 1,000 documents to this list in preparation for the California trial settings.

Mr. Kaufman - Direct

- Q Okay. And to your knowledge, did Mr. Girardi or his firm have any input into this exhibit list?
 - A This exhibit list was provided to the Girardi firm, as it was prepared by our firm, leading up to our trial. There may be documents on this that Mr. Girardi's firm added to. I don't see them, but for the most part, given the MDL numbers on this document, I know that these are documents from the MDL that we provided in the list itself.
- Q And when you say, from the MDL numbers on the document, what do you mean?
- A The documents are listed by Bates number, and the AV MDL Bates numbers are Bates numbers that were applied by GSK when GSK produced the documents to the Plaintiffs' Steering Committee in the Avandia MDL. That's how they designated their documents.
- Q And do you see any documents on here that say AV-CA-JCCP?
- A I don't.

- MR. ZONIES: May I approach, Your Honor?
- 21 THE COURT: You may.
- BY MR. ZONIES:
- 23 Q Mr. Kaufman, I have handed you --
- MR. ZONIES: Your Honor, I move for admission of Exhibit 7.

ase 2:07-md-01871-CMR Document 3963 Filed 04/17/14 Page 75 of 107 Mr. Kaufman - Direct 75 Any objection? 1 THE COURT: MR. GIRARDI: We have no objection. 2 3 objection. Thank you. It is admitted. 4 THE COURT: (Petitioner's Exhibit 7, trial exhibit list, 5 is admitted into evidence.) 6 7 BY MR. ZONIES: Mr. Kaufman, I have handed you Exhibit 8. Do you 8 have that in front of you? 9 10 Α Yes, I do. And what is Exhibit 8? What is your appreciation of 11 what Exhibit 8 represents? 12 Exhibit 8 is a joint witness list for trial that was 13 filed in the California JCCP, relating to the case, 14 15 Nancy LeVoise versus SmithKlineBeecham/GlaxoSmithKline. And again, what is your understanding of who the 16 17 counsel is for Ms. LeVoise? My understanding is that, counsel for Ms. LeVoise 18 was the Girardi Keese firm. And this -- this document, 19 20 witness lists for trial, has a complaint filed date.

What is that date that that was filed in California?

you see that on the first page, under the caption,

The complaint file date is May 19th, 2009.

Okay. And than what is the trial date?

Witness Lists for Trial?

21

22

23

24

25

Α

Mr. Kaufman - Direct

76

- A April 11th, 2012.
- Q All right. And let's take a look at some of the
- 3 plaintiffs -- well if you turn to the second page,
- 4 actually, there is a signature block. Do you see that
- 5 signature block, the second one down?
- 6 A Yes.

1

- Q And who does it purport to be the signature of on
- 8 the document?
- 9 A It looks like Keith Griffin.
- 10 Q At what law firm?
- 11 A At Girardi Keese firm.
- 12 Q And listed as attorneys for the plaintiff in the
- 13 case?
- 14 A Yes, Nancy LeVoise.
- 15 Q Exhibit A is the plaintiff's trial witness list, do
- 16 you see that?
- 17 A Yes.
- 18 Q All right. Now, there are a number of -- in column
- 19 three, there appear to be, like, time numbers. Do you
- 20 know what those are?
- 21 A Yes. Those are the deposition cut times for each of
- 22 these witnesses, so when we were preparing for trial and
- 23 did deposition cuts for each of these witnesses, when we
- 24 were preparing to play their videos during trial, those
- are the time lengths for those videos.

- Okay. And did you actually participate in the Q creation of this document and, also, the cutting of those depositions?
- Α Yes.

1

2

3

4

5

6

7

8

9

10

12

13

14

15

16

17

18

19

20

21

22

23

- And I just want to go through a few of these, if we Q can, Mr. Kaufman. The first one that says, Susan Abelson, R.N., plaintiff's treating physician, do you see that?
- Α Yes.
- Q You understand that that's Ms. LeVoise's doctor in the case? 11
 - That's my understanding, yes. Α
 - Okay. So I am going to call things like that case Q specific, and then, if we talk about somebody like Allaster Benbot (ph), that's a GSK employee. Do you see that second one?
 - Yes, and Dr. Benbot was a witness whose deposition I took in the UK. Do you recognize -- do you know if Girardi Keese had any role, whatsoever, in the deposition of Mr. Benbot, that GSK employee?
 - I don't believe they did, no.
 - Okay. So, I'll call things like that, sort of the, general liability witnesses. Does that make sense to you, the distinction?
- 25 Α Yes.

- Q Okay. So, Joanna Bulsreck (ph), do you know whether the MDL or Mr. Girardi and Girardi Keese took that deposition?

 A Counsel for the MDL took that deposition.
 - Q Okay. Mr. Cardinale (ph), in particular?
- A Yes.

- Q Okay. And these are -- these are plaintiff's trial witnesses, the witnesses that, apparently, Girardi Keese intends to call at his trial in California, correct?
- A That's my understanding, yes.
- Q All right. The next GSK employee is David Brand (ph). Do you know if the MDL took that deposition or was it Girardi Keese?
 - A The plaintiffs' lawyers and the MDL took the deposition of David Brand.
 - Q Elliot Brinton, it says, plaintiffs' expert. We discussed Dr. Brinton a little earlier. Do you know if Dr. Brinton was, indeed, found by, worked up and presented by the MDL at a <u>Daubert</u> hearing in the MDL or did Mr. Girardi and Girardi Keese do that?
 - A No. Dr. Brinton's work on this case was worked up through the MDL and was subject to <u>Daubert</u> hearings, here, in this Court, and he survived those hearings.
- Q And, then, if we look at -- I'll just summarize -- Buckingham, Caponie, Carr, all the ones that say GSK

Mr. Kaufman - Direct

- employee, Kollitz, Kekettle, Kolier, Rahl, even these third-party witnesses like, Marty Fried, Jeffery Fried, Dr. Garnier, the CEO at one point in time, Dr. Gavin, GSK's expert, Dr. Gibbs, do you know who prepared and took the depositions of all of those people that I just listed? Was it MDL lawyers or was it Mr. Girardi and Girardi Keese?
 - A These would all be MDL lawyers.
 - Q And if we turn to the next page, would that same thing be true for every witness on that next page, other than the case specific witnesses, as far as you know?
- A That's true. As far as I know, that's true.
- 13 Q So, Dr. Hefner, David Harrison, Mark Hiese, Dr.
- 14 Holme, were the MDL -- do you know, whether or not --
- 15 indeed, you may know this. Do you know whether or not
- 16 the MDL flew to the UK to take the deposition of Dr.
- 17 Holme?

1

2

3

4

5

6

7

8

9

10

11

- 18 A I do know that the MDL flew to the UK to take the deposition of Dr. Holme.
- Q Do you know, did Girardi Keese pay any of the expenses associated with that trip?
- 22 A I don't know if they did.
- 23 Q Dr. Jewell is an MDL expert, is that right?
- 24 A Yes.
- 25 Q And I could go on through this list. I don't want

	Mr. Kaufman - Direct 80
1	to take up too much more of the Court's time.
2	Dr. Steven Nissen, do you know if Girardi
3	Keese had any part or any role in any of the depositions
4	of the general liability experts and/or the general
5	liability, general causation expert witnesses listed as
6	their plaintiffs' experts in their California trial
7	case?
8	A To my knowledge, they did not.
9	Q Thank you.
10	MR. ZONIES: I would move admission of Exhibit
11	8, Your Honor.
12	THE COURT: Any objection?
13	MR. GIRARDI: No objection.
14	THE COURT: Thank you. It's admitted.
15	(Petitioner's Exhibit 8, trial witness list,
16	is admitted into evidence.)
17	MR. ZONIES: I have nothing further for the
18	witness, Your Honor.
19	THE COURT: Thank you. Cross-examine, please?
20	MR. GIRARDI: Very well.
21	<u>CROSS-EXAMINATION</u>
22	BY MR. GIRARDI:
23	Q We were in the California cases about three years, I
24	think, before you came into them, isn't that correct?
25	A I think that's right, yes.

- Q And you had nothing to do with the settlement negotiations of our cases with the defendant, isn't that correct?
 - A That's correct.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

- Q And as a matter of fact, we had our own -- we made our own demands for documents, of which the defendant said, please just get those from the MDL. You know that, don't you?
- A I didn't know that. I know that our firm made those documents available to you. The MDL documents, we made them available to you and your firm.
- Q Right. And that is because, the defendant said, we don't want to do this again. We've done it. We appreciate the fact that you're entitled to it, but we've already done it, so please, get a copy of these documents. That's what happened, isn't it?
- A I don't know that.
- Q Okay. And, then, of the major witnesses that are going to put the case together, for example, Dr.
- Maracangus (ph), he was the key guy for the plaintiffs'
 case, wasn't he?
 - A I'm sorry, could you say that name again?
- 23 Q Maracanqus.
- 24 A I don't know who that is.
- Q Okay. And the fact of the matter is, that we've

Mr. Kaufman - Cross

82

made requests of the defendant to take some of these 1 party -- some of their own employee depos, and they told 2 3 us that they didn't want to do that because the parties had been deposed already, and would we please get the 4 depositions that are already on file, isn't that true? 5 I don't know that. Α 6 7 Okay. You, certainly, did not participate in the 8 workup of any of our cases for trial, did you? I did not participate in the workup of the case 9 10 specific elements of your cases, no. And you did not assist in the 14 million in costs 11 12 that we incurred to properly develop these cases, right? I don't know anything about your spending on your 13 14 cases, no. 15 Okay. MR. ZONIES: Nothing further, Your Honor. 16 17 THE COURT: Thank you. Any redirect? 18 MR. GIRARDI: Nothing, Your Honor. Thank you. You may step down. 19 20 (Witness excused.) THE COURT: Mr. Zonies? 21 22 MR. ZONIES: If I may have a moment, Your 23 Honor? 24 THE COURT: You may. 25 (Pause in proceedings.)

MR. ZONIES: Nothing further. From the 1 plaintiffs, there may be something. 2 3 MR. GIRARDI: Nothing further from the Plaintiffs' Advisory Committee, Your Honor, except that 4 we do intend to file a petition for our fees and costs 5 associated with having to travel to this hearing and 6 work today. 7 8 THE COURT: All right. So, the petitioner, the Plaintiffs' Advisory Committee rests, at this time. 9 10 Mr. Girardi, do you have any rebuttal evidence to 11 present? 12 MR. GIRARDI: No, Your Honor. 13 14

THE COURT: All right. Then, the record is closed, as to documents and exhibits and testimony. However, I will give you that opportunity to give me a brief on whatever you think needs to be supplemented, by way of argument, Mr. Girardi. I think I understand your argument, but I'd like you to get it all in line. long as you have --

MR. GIRARDI: All right.

15

16

17

18

19

20

21

22

23

24

25

THE COURT: -- a full copy of all of the exhibits that I think were just introduced here.

MR. GIRARDI: Your Honor, I'll be very -- I'll be very brief. Your Honor, there is no question that Sizemore worked for us for four months. There is no

question about it. There is no question that he was gone after that, with another law firm, and he billed for the other law firm, not for us. There is no question that there is one document that covers cases that we actually had, at the time of the signing of the document.

It didn't cover other documents. It didn't cover other cases. It just covered those particular cases. We also admit that there were 20 cases that were on a holding pattern. And I think it's appropriate that the cases that we actually had, at the time that the first agreement was signed by Keith Griffin, and there is no further signatures, that those are part -- they should be subjected to the fee.

And I think the 20 cases that are in your Court, obviously, have to be subjected to the fee. With respect to all of the others, the rudimentary stuff that we received from the Committee, really, was just to duplicate -- just to save the defendant from having to do it again, with respect to our requests.

The key, in this case, were the fact of our negotiations, the fact of how we built up all of our cases. It didn't have anything to do with the MDL, and the fact of the matter is, we spent a fortune to do it, to make sure our clients were well taken care of. And

for the MDL to weigh in, to ask for all of this money 1 from us, other than the cases that were in our 2 3 possession at the time the agreement was signed, and the 20 before the Court, we think is truly inappropriate, 4 we'll submit. 5 Thank you. Would you like to THE COURT: 6 7 submit any additional briefing? 8 MR. ZONIES: I'm sorry, Your Honor, you cut out there. 9 10 THE COURT: Would you like to submit any additional briefing, before I render --11 12 MR. ZONIES: Yes, Your Honor, that would be 13 wonderful if you would --THE COURT: That's what I said earlier. 14 15 MR. ZONIES: -- if you would give us the 16 chance. 17 THE COURT: You are permitted to do that. 18 MR. ZONIES: Okay, Your Honor, we accept the nice invitation. 19 20 THE COURT: You're welcome. MR. GUSSACK: Your Honor, would we be given an 21 22 opportunity, then, to reply? 23 THE COURT: Yes, you would. 24 MR. GUSSACK: Thank you. THE COURT: And I will set that, how about 25

seven days, so you can review all of the documents, 1 here, and give me your best argument? 2 3 MR. GIRARDI: Your Honor, I appreciate that. 4 Seven days is fine. THE COURT: All right. And another seven 5 days, if you need it, thereafter, and I will review 6 those documents and make my decision. So --7 8 MR. GRIFFIN: Your Honor, could we ask --THE COURT: Yes, Mr. Griffin? 9 10 MR. GRIFFIN: Your Honor, may we ask a member 11 of either of the two sides there to send us a copy of 12 the exhibits that were entered into evidence today? MR. ZONIES: We'll get those out tonight to 13 14 you. 15 THE COURT: Yes. Those will be FedEx'd to you 16 tonight. 17 MR. GRIFFIN: Thank you, Your Honor. 18 THE COURT: You're welcome. And with that, the motion on the Rule to Show Cause is held in abeyance 19 20 and under advisement, pending final briefing. I do not believe we will need another hearing, however. As to 21 22 the exhibits, they will be formally presented by FedEx

from the PAC to Girardi Griffin, but I believe you have

access to just about every one of them already, because

they're all of record in one Court or another. Now,

23

24

with a three minute interruption -- let's make it five
-- I know I have a criminal proceeding at 3:00, but I do
want to address the next matter. We have got to address
that, first and foremost.

So can everybody take five minutes, please? Thank you.

(Recess, 2:23 p.m. to 2:34 p.m.)

THE COURT: Good afternoon, again.

MR. ZONIES: Good afternoon.

MR. GUSSACK: Good afternoon.

THE COURT: At this time -- please be seated, everyone -- we will be addressing GSK's motion, which is, in the first instance, asking for a temporary restraining order, and I would like to address this as the claim to compel arbitration and to enjoin initiation or pursuit of litigation, filed by GSK.

It has been responded to by Mr. Girardi, so we would like to ask GlaxoSmithKline, Ms. Gussack, to address this matter, in the first instance. Please lay out -- we already have an idea of the procedural posture, here, but please, as quickly as you can, let's get to the heart of the matter, which is, as I understand it, to be the Master Settlement Agreement that was signed by Girardi Keese on behalf of their respective clients in which GSK and Girardi Keese

decided that they would settle all of their Avandia claims, dated 2012, had also included -- does also include an arbitration provision to which the parties agree that they will submit differences of position as to actual amounts, per case, and you have asked to compel that arbitration.

MR. GUSSACK: Thank you, Your Honor. Mr Girardi and Mr. Griffin, good afternoon. May I approach, Your Honor?

THE COURT: You may.

MR. GUSSACK: I believe that you said that the Court did not have the Master Settlement Agreements available to it. Of course, these are being submitted under seal, and while I enjoyed having the presence of my colleagues, and the plaintiffs' bar present, I am going to maintain a very strict confidential discussion of these terms, so that I am not in violation of the confidentiality terms, and I am confident that Mr. Girardi and Mr. Keese will do the same.

Your Honor, in a nutshell, we come to you simply for the Court to compel the arbitration provision that, as you noted, is present in the Master Settlement Agreement. I find this to be a, somewhat, anomalous, circumstance.

Here, I stand, 60,000 plus cases resolved on

behalf of GSK, amongst the most challenging, aggressive, assertive, creative plaintiffs' counsel in the country, in which GSK has managed to resolve, with a variety of terms and agreements over time, even as we dealt with the terms and the implementation effectuation of these agreements, never has GSK been in a position where it has not been able to achieve, successfully, the implementation of the Master Settlement Agreement.

This Master Settlement Agreement was entered, as the Court is aware, in August, 2012. A year after it was entered into, Mr. Griffin advised us that he still did not have all of the information about all of the plaintiffs that was necessary. We understood that. That happens frequently. We worked with Mr. Girardi and Mr. Griffin, and their selected facilitators, Justice Trotter and Justice Panelli, to assist, to respond and to implement.

I have to tell the Court that, at every turn, when we did not agree with Mr. Girardi or Mr. Griffin's interpretation of provisions, we would be told that Mr. Girardi was going to file ex parte proceedings before Judge Berle, with respect to claimants in the settlement. We reminded Mr. Girardi, on multiple occasions, that there is an arbitration provision.

And as recently as January, I believe, of this

year, I wrote Mr. Girardi, and I said, Your Honor, "If we are unable to resolve the matters that are impeding resolution, I am going to remind you about paragraph five and ten of the Master Settlement Agreement, where we are supposed to jointly agree upon an arbitrator and submit our differences to arbitration", all differences. Whether it's about qualification; whether it's about leal interpretation, we are supposed to submit them to arbitration.

I received no response from Mr. Girardi, until I received a unilateral demand of ADR for ten claimants of what is supposed to be a Master Settlement Agreement that covers over 4,000 claimants. In the course of the last two years, we have managed to qualify and agree on some portion of those 4,000 claimants, and we have, in fact, advanced a substantial portion of dollars in partial payment of those claims.

But the differences that continue to plague us, including the common benefit fee, including lien issues and including the qualification of the remainder of the affected claimants has resulted in our standoff, at this time.

I cannot say that anyone has ever called me despicable or accused my client of being fraudulent in the course of negotiations about the implementation of a

settlement agreement, but I stand before you so accused, GSK so accused, and our concern that no Court has any interest in this agreement, other than this Court, because of the MDL claimants who are part of it, because of the common benefit fee that impedes forward movement, because of the lien resolution issues that this Court is familiar with. There is no Court that is sitting as a qualified settlement fund judge.

Judge Berle, as you heard, under oath from Mr. Griffin, has no supervisory authority over this matter. And all we seek from this Court, Your Honor, is the effectuation of the arbitration provision under the MSA. This Court need not decide the application of any term, but simply allow the parties to do what they contracted to do, which was to arbitrate the differences.

And to the extent that we have a difference about which arbitrator, I would be happy to suggest that Special Master Merenstein help us work through that issue.

We sought a TRO, Your Honor, simply because in the last few weeks, Mr. Girardi continues to threaten us with ex parte proceedings before Judge Berle as to this settlement agreement and claimants within it. And it is our view that the status quo should hold, that we would be caused irreparable harm, should there be fractionated

litigation of this issue, and that we simply need to proceed under the terms of the MSA and arbitrate our differences.

Frankly, Your Honor, I would like to suggest, and I've told Mr. Girardi this as recently as last week, I think the issues that separate us are modest. I have consulted with Justice Trotter, his designated settlement assistant, to identify issues, and yet, we have not found common ground. I am happy to take those issues up with Special Master Merenstein, with Justice Trotter and Special Master Merenstein. I am willing to do anything I can to be relieved of the cloud that has burdened us on this settlement agreement.

But, Your Honor, if that is not going to be forthcoming promptly, then, I would simply ask that our papers, which seek to compel arbitration, be considered promptly, and that we be permitted to select a CPR arbitrator that we sought for the entire agreement or have the benefit of a third-party's assistance, enjoining to a neutral arbitration venue.

THE COURT: All right. Thank you. Can you just inform the Court, has there been any document or litigation filed before any California Court, Federal or State, concerning this matter?

MR. GUSSACK: Your Honor, as recently as last

evening, when we checked, no -- no document had been filed by Mr. Girardi. However, three letters that I have received in the last ten days, threatened that an ex parte hearing was sought, had been scheduled for March 24th, and actually, on prior dates, I've been told that Mr. Girardi had reported me to the District Attorney's Office in California, but I have not seen any such papers.

And, Your Honor, if I might hand up my request to -- the request to -- if the Court would like them, I certainly can hand up to the Court, the correspondence, both, seeking the appointment of an agreed upon arbitrator and the letters from Mr. Girardi, suggesting that he was proceeding, ex parte, in California. But, to answer the Court's question, as far as I know, no document has been filed in Judge Berle or in California, as to the settlement agreement.

THE COURT: And is the request of this Court, for a temporary restraining order, which, of course, is extraordinary, in terms of its timing, is that based on the alleged repeated threats, Ms. Gussack, to go elsewhere? Is that to maintain the ability of this Court to interpret its own orders and enforce its own Rules or is it something else? I just need to know what the TRO basis is.

MR. GUSSACK: Yes, Your Honor, it's as -- it's for both grounds. It's to allow this Court to enter -- to order arbitration, so that we may proceed to resolve an agreement that implicates the interests of this Court, both because of the MDL plaintiffs that are within the settlement, because of the orders of this Court, and because we seek, in diversity, this Court's jurisdiction over this matter, and to implement the settlement terms.

It is also because we believe that to have piecemeal litigation of State Courts, regardless of where they sit, in which there is conflicts between what a State Court Judge may conclude about Your Honor's orders or lien resolution or common benefit fee or whether this should be subject to arbitration as it plainly must be by the terms of the order, would be irreparable harm and should not be tolerated.

THE COURT: All right. Can you please state for the record the date upon which the Court approved the stipulation on this Master Settlement Agreement for the record.

MS. GUSSACK: Well, Your Honor, the stipulation and order placed the cases in administrative suspense as a result of the settlement was dated in October 4th, 2012.

THE COURT: Were there any other documents approving the stipulation of the Master Settlement Agreement or any other cases? Which, by the way, if it's the same order that you're referring to that was introduced in the companion litigation heard earlier today, has 25 cases on it, not 20, just wanted to again clarify that.

MS. GUSSACK: Yes. Thank you, Your Honor.

I'm not aware of any other order entered in this Court

with respect to notification of the settlement and civil

suspense. I believe Judge Berle similarly has put in

suspense the cases that were filed before him.

THE COURT: But is there any way that Judge

Berle has signed a comparable agreement in California?

MS. GUSSACK: No, Your Honor. I'm not aware

of any order entered by Judge Berle with respect to the

settlement.

I believe Mr. Girardi notified Judge Berle of the settlement, notified him that he intended to use Justice Trotter and Justice Panelli to assist him in the effectuation of the agreement, and, in fact, the settlement agreement contemplates that Justice Trotter and Justice Panelli will certify the qualification of claimants to meeting the terms of the settlement agreement.

While that has not occurred, I'm not aware of 1 any order entered by Judge Berle with respect to any 2 3 term or approval of the settlement. 4 THE COURT: Thank you. 5 MS. GUSSACK: Thank you, Your Honor. THE COURT: Mr. Girardi, would you like to 6 7 respond, please? 8 MR. GIRARDI: Yes. Thanks very much, Your 9 Honor. 10 Your Honor, first of all, we're named

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

personally here, and it seems that California jurisdiction would be appropriate. This case has gone on for five and a half years before one Court. Court has handled all the issues that have arisen, and it seems to us that clearly this -- this matter properly belongs where the case has been handled for the five and a half years, in which the Judge is familiar with all of the settlement agreements. Contrary to counsel's --

THE COURT: Is there another settlement agreement other than the Master Settlement Agreement, Mr. Girardi? Is there another one floating around somewhere in space?

> MR. GIRARDI: No, Your Honor.

THE COURT: Other than the one that's file here in Court?

MR. GIRARDI: That's the only one.

THE COURT: Well, then, how does --

MR. GIRARDI: He has been --

THE COURT: Fine. What else do you want to argue to the Court?

MR. GIRARDI: Well, here's the -- here's the problem. This settlement is the total con game. I've never gone through such despicable conduct in my life as here. This company admits they owe money and then they don't pay it. These clients have been out there for a year and a half now as all of the nonsense of -- of this company has taken place. So they don't -- they don't simply want to pay.

I don't blame them, but they shouldn't have entered into the agreement if they didn't want to pay. And we have to get this issue heard to show that the -- the objections, Your Honor, I could spend a lot of your time, but you have a 3:00 -- have been totally absurd.

THE COURT: I'm not going to be the arbitrator that gets appointed here, so don't bother with that.

But you have to explain to me how you have not agreed to submit to the arbitration clause that is clearly in the Master Settlement Agreement that you and Mr. Griffin acknowledge covers all of your claimants.

MR. GIRARDI: Your Honor, I don't think it

covers fraudulent conduct, that's the only thing.

Everything else it does. And then what we did, we said,

listen, this case is pending in California. Here is the

alternative dispute resolution. We demand that

arbitration be forwarded to alternative dispute

resolution.

We've got 60 retired Judges. We didn't select any Judge, and -- to get the ball rolling. They then write to alternative dispute resolution saying, absolutely not, we refuse to go to arbitration. So I need -- I need a Court order from these people to make them pay what they said they agreed to pay. And the common benefit fund is not an issue. They withheld that. We agreed that they would withhold that until you made a decision and so forth. So that doesn't hold anything up.

The fact of the matter is, in writing, they agreed they owed these sums, and in writing, they refused to pay it. So we can't -- I can't live this way. These people have been waiting for this money now for two years since we told them of "the settlement," and I have to get --

THE COURT: Do you agree -- do you agree, Mr. Girardi, with Ms. Gussack's representation just now heard in Court that there are ten of your clients at

issue here?

to me --

MR. GIRARDI: Oh, no, Your Honor. Those are just the ones we -- we initially filed on. There are 1,400 of the cases that are at issue.

THE COURT: As to which ones get how much money? Is that what you're talking about?

MR. GIRARDI: Yes, I would say, each -- that they -- that they qualify to start with. Besides that, there's another 90 cases that they wrongfully did not permit recovery that we have all the documents on. They have all the documents on. It was just a con game. That's the truth.

THE COURT: Then why -- why are you not agreeing to end this impasse and submit to a neutral arbitrator as outlined in the Master Settlement Agreement? It would seem to me that you and GSK will not agree. So someone in the middle has got to help you both. Why wouldn't you agree to that, sir? That's why we're here today.

MR. GIRARDI: Your Honor, if the question is directed to me --

THE COURT: That's why we're here today.

MR. GIRARDI: -- if the question is directed

THE COURT: It is.

this?

MR. GIRARDI: -- we think it's -- we think that it's appropriate for a case that's been in the California Courts for five and a half to six years should be arbitrated in California, because that's where the case is. And we even told them, we'll go to ADR, that's -- or to JAMS or to anybody, any place. We said that.

THE COURT: Now, really, just talking in general terms, you hired JAMS to work for you. That would not make them a neutral, would it? You must have thousands of other arbitrators that you could call a neutral, but JAMS wouldn't be one of them. Besides, it says right in the Master Settlement Agreement -- is it paragraph ten -- that, "They will be excluded from the determination of who is to be a neutral arbitrator."

MR. GIRARDI: Your Honor, that's why -THE COURT: Don't you want to proceed under

MR. GIRARDI: -- I'm sorry, Your Honor, I didn't mean to --

THE COURT: Don't you want to proceed under this?

MR. GIRARDI: Your Honor, I -- Your Honor, I really don't because of the fraud, and I think we have real causes of actions due to fraud. On the other hand,

I'm the one that said to them, let's arbitrate it, and we gave them this -- there's a list of 65 arbitrators in ADR, not JAMS, Your Honor -- ADR. It's the most respected organization out here, and they told us to pound salt.

THE COURT: All right. I am going to ask for the letters that you referred to, and I am going to evaluate this case right now, not on the ultimate decision but on whether or not a TRO should issue. It is clear to me that Mr. Girardi does not intend to subject his cases to the MDL supervision for whatever reason. However, this Master Settlement Agreement belongs nowhere else. So I am assuming jurisdiction.

And whether California law applies or not to these arguments will be a matter that you can brief.

However, a TRO has been requested, and I assume that is to get this thing moving. So let's see what you have to give me.

MS. NAST: Thank you, Your Honor.

I'm going to hand to the Court and I know that Mr. Girardi has a copy of my January 28, 2014 letter seeking a discussion to agree on a joint neutral arbitration, a neutral, for purposes of arbitration under the agreement, Mr. Girardi's March 5th, 2014 letter in which he, on behalf of ten claimants,

unilaterally advises that he's using ADR, and then our March 10, 2014 letter to Mr. Girardi and to Mr. Griffin identifying our request that we are submitting the entire Master Settlement Agreement and all terms and all claimants to the International Institute for Conflict Prevention Resolution known as CPR, Your Honor, our motion to compel arbitration and the TRO is in diversity, a breach of contract action and seeking to enforce the arbitration that is the basis -- the law that is applicable here is Delaware law.

And there is no pending lawsuit in California that would make this settlement subject to California law or any special California proceedings. Let me hand these up.

THE COURT: Thank you. These letters have been identified by date and by subject matter, Mr. Girardi. Do you have any question as to whether or not you received these letters?

MR. GIRARDI: No, Your Honor. We received them. We don't want to go there because they're all hooked up with -- with defendant corporations all over the world. I know that. We need somebody --

THE COURT: Well, I know -- I know who is not hooked up with any corporation, and that is our Master. So we can off you the neutral that would be Bruce

Merenstein, the Special Master in Avandia, but I would not force you into any one place. I just don't see how you can't try to resolve this with getting a neutral arbitrator. I don't want to be the one in a position to choose that, but for now, I am going to grant the temporary restraining order.

It is a temporary restraining order, because it will enjoin you, Mr. Girardi, and your employees, your agents and assigns, from filing or pursuing litigation against GSK in violation of the terms of the Master Settlement Agreement entered between you and GSK -- there is no question about that on this record -- for the reasons set forth that were set forth right here in Court.

I know that you think that this Court is depriving you of your choice of forum, but that is not an issue on choice of law. The contract between you and GSK needs to be interpreted and only this Court should be doing that, and I am willing to give you another seven days from today to brief all of the issues that you think are appropriate, if you can't resolve within 24 hours a neutral to which you can both submit the remaining claims, either ten or 1,400, it doesn't matter to me. So I will require your response as to that issue within 24 hours.

If that is not to be an agreement, then I will consider appointing Mr. Merenstein in any event as the neutral, because somewhere, somehow there has to be a forum to address this impasse. And charges of despicable conduct or fraudulent conduct are really something that need to be proven in court, and I'm not taking a position with that. But I will say that out of 60,000-plus, 65,000, even higher-plus settlements, that GSK has arranged with State and Federal claimants, whether they had cases in the MDL or not, I've never run into this problem.

So this is a new one, and all of a sudden fraudulent conduct after they've paid out, you'll have to prove that, sir. But if you think that they're holding back because they don't want to pay you, then get before an arbitrator, get rid of the reasons that you think they're holding on to it, and then see where you are.

Everybody else has gone through this process, Mr. Girardi. I'm not so sure why you can't. I think you're a bright man. You're obviously successful, got Mr. Griffin assisting you. It's time. Let's get this over with. You already have an agreement. Let's make sure that it's honored, and that's all we're going to do on this matter today.

MR. GIRARDI: Your Honor, that's what we wanted to do, is honor the agreement so we could get the money for these poor people we represent. THE COURT: I hope you recognize that that's my goal. We're adjourned. MS. GUSSACK: Thank you, Your Honor. (Proceedings concluded at 2:59 p.m.)

1	<u>INDEX</u>
2	
3	PETITIONER'S OPENING STATEMENT PAGE NUMBER
4	By Mr. Zonies 7
5	
6	RESPONDENT'S OPENING STATEMENT PAGE NUMBER
7	By Mr. Girardi 11
8	
9	PETITIONER'S WITNESSES DIRECT CROSS REDIRECT RECROSS
10	Vance R. Andrus
11	By Mr. Zonies 43 67
12	By Mr. Girardi 61
13	Justin Kaufman
14	By Mr. Zonies 68
15	By Mr. Girardi 81
16	
17	PETITIONER'S EXHIBITS ADMITTED INTO EVIDENCE
18	1 Document 108 from MDL Number 1871 45
19	2 Attorney Participation Agreement 48
20	3 Letter dated 8-31-09 from Vance Andrus 50
21	4 Letter dated 9-21-09 from Vance Andrus 55
22	5 PTO 70 of MDL 1871 58
23	6 Document 2740 of MDL 1871 60
24	7 Trial exhibit list 78
25	8 Joint witness list 80

I, Donna M. Anders, do hereby certify that the foregoing is a true and correct transcript from the electronic sound recordings of the proceedings in the above-captioned matter.

Algebra Donna M. Anders

CERTIFICATION

I, Donna M. Anders

Donna M. Anders